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On April 17–18, 2014, basic and trans-
lational scientists and clinicians convened
in San Francisco, CA for a conference in
fetal stem cell transplantation, stem cell
biology, tolerance, and gene therapy.
The purpose of the meeting
(http://pedsurglab.surgery.ucsf.edu/news–
events/fetal-symposium-2014.aspx) was
to outline the goals of in utero trans-
plantation, review the barriers that have
been encountered, and learn about new
developments that can be applied to the
field.
Information discussed at this confer-
ence will help pave the way for develop-
ing novel strategies to achieve therapeutic
engraftment levels in the fetus, and iden-
tify ways to safely translate these strategies
to a wide range of clinical applications.
We held a final consensus session to
achieve an international agreement for
future pre-clinical and clinical studies of
in utero hematopoietic cell transplanta-
tion (IUHCT).We agreed on the following
items:
• In utero transplantation is a viable
strategy to treat fetuses with selective
congenital disorders.
• Given recent publications that the
maternal immune response can limit
engraftment, the clinical strategy for
IUHCT should involve transplanta-
tion of autologous or maternal-derived
cells. The host immune response may
be a limiting factor that might be
circumvented with early cell delivery.
• The fetal microenvironment plays
a primary role in supporting the
engraftment and expansion of trans-
planted cells and requires further
investigation.
• Recent data from large animal stud-
ies suggests that intravascular injection
may be the delivery route of choice to
achieve engraftment of hematopoietic
stem cells in the fetus.
• Currently, there is no proven safe
method of host conditioning in the
fetus. Until specific, non-toxic condi-
tioning methods (such as antibody-
mediated depletion of host HSC) are
optimized in pre-clinical models, large
cell doses should be used to overcome
host competitive barriers.
• Experimental model data are suffi-
cient to warrant a phase 1 clinical
trial of IUHCT for select fetuses. The
most suitable hematological diseases are
hemoglobinopathies such as sickle cell
disease and thalassemia, given their high
morbidity/mortality, the availability of
reliable prenatal screening programs,
and the paucity of optimum postnatal
care options.
• The value of alternative cells, such as
mesenchymal stromal cells (MSC) and
amniotic fluid-derived cells, for other
appropriate congenital pathologies war-
rants investigation.
• Reports of using MSC in utero to treat
osteogenesis imperfecta (OI) in a lim-
ited number of patients are promising
and suggest that, after optimization,
MSC could be used to improve/
treat OI.
• Treatment of the fetal patient using gene
therapy and gene-modified cells have
great future potential and should be
fields of active investigation.
• A new society focused on fetal stem cell
transplantation and gene therapy will be
formed (FeTIS: Fetal Transplantation
and Immunology Society), with
the mission of accelerating clinical
applications of stem cell transplan-
tation and gene therapy approaches
to treat fetuses with congenital
anomalies.
• The society should develop and
maintain an international registry of
treated patients and their outcomes
to facilitate reporting and sharing
of results. This database will not be
publicly accessible and data will be
anonymized.
• The society will provide a forum for
members to share best practice and clin-
ical governance for in utero stem cell and
gene therapy cases.
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